Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Mar;23(3):267–271. doi: 10.1111/j.1365-2125.1987.tb03044.x

Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.

P Seideman, K O Borg, K Haglund, C Von Bahr
PMCID: PMC1386223  PMID: 3567041

Abstract

The antihypertensive effect of alprenolol has been studied before, during and after additional pentobarbitone treatment. The combined alprenolol-pentobarbitone treatment significantly decreased alprenolol levels by 59% and 4-hydroxyalprenolol by 24%. The effect was significant after three doses and declined over 4-5 days after pentobarbitone withdrawal. The decreased alprenolol plasma levels were associated with increased pulse rate (6%), and systolic (8%) and diastolic (9%) blood pressure. The inhibition of exercise tachycardia by alprenolol was reduced by 18% at the end of pentobarbitone treatment compared to initial monotherapy with alprenolol. The interaction is probably clinically important in those patients with hypertension and angina pectoris that are treated with barbiturates and alprenolol.

Full text

PDF
267

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Lind M., Mellström B., von Bahr C. Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol. J Pharmacokinet Biopharm. 1977 Jun;5(3):193–205. doi: 10.1007/BF01065395. [DOI] [PubMed] [Google Scholar]
  2. Alván G., Piafsky K., Lind M., von Bahr C. Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther. 1977 Sep;22(3):316–321. doi: 10.1002/cpt1977223316. [DOI] [PubMed] [Google Scholar]
  3. Breckenridge A., Orme M. L., Davies L., Thorgeirsson S. S., Davies D. S. Dose-dependent enzyme induction. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):514–520. doi: 10.1002/cpt1973144part1514. [DOI] [PubMed] [Google Scholar]
  4. Collste P., Borg K. O., Aström H., von Bahr C. Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol. Clin Pharmacol Ther. 1979 Apr;25(4):416–422. doi: 10.1002/cpt1979254416. [DOI] [PubMed] [Google Scholar]
  5. Collste P., Seideman P., Borg K. O., Haglund K., von Bahr C. Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol. Clin Pharmacol Ther. 1979 Apr;25(4):423–427. doi: 10.1002/cpt1979254423. [DOI] [PubMed] [Google Scholar]
  6. George C. F., Lewis P. J., Petrie A. Clinical experience with use of ultrasound sphygmomanometer. Br Heart J. 1975 Aug;37(8):804–807. doi: 10.1136/hrt.37.8.804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Grundin R., Moldéus P., Orrenius S., Borg K. O., Skånberg I., von Bahr C. The possible role of cytochrome P-450 in the liver "first pass elimination" of a beta-receptor blocking drug. Acta Pharmacol Toxicol (Copenh) 1974 Sep;35(3):242–260. doi: 10.1111/j.1600-0773.1974.tb00744.x. [DOI] [PubMed] [Google Scholar]
  8. Haglund K., Collste P. Time course of blood pressure, pulse rate, plasma renin and metoprolol during treatment of hypertensive patients. Eur J Clin Pharmacol. 1980 May;17(5):321–328. doi: 10.1007/BF00558443. [DOI] [PubMed] [Google Scholar]
  9. Haglund K., Seideman P., Collste P., Borg K. O., von Bahr C. Influence of pentobarbital on metoprolol plasma levels. Clin Pharmacol Ther. 1979 Sep;26(3):326–329. doi: 10.1002/cpt1979263326. [DOI] [PubMed] [Google Scholar]
  10. Villén T., Petters I. Analysis of barbiturates in plasma and urine using gas chromatography without prior derivatization. J Chromatogr. 1983 Mar 18;258:267–270. doi: 10.1016/s0021-9673(00)96423-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES